Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Revenue (2016 - 2025)

Historic Revenue for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to $15.1 million.

  • Enanta Pharmaceuticals' Revenue rose 354.62% to $15.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.3 million, marking a year-over-year decrease of 341.69%. This contributed to the annual value of $65.3 million for FY2025, which is 341.69% down from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Revenue of $15.1 million as of Q3 2025, which was up 354.62% from $18.3 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' Revenue's 5-year high stood at $27.6 million during Q4 2021, with a 5-year trough of $14.6 million in Q3 2024.
  • Moreover, its 5-year median value for Revenue was $18.7 million (2022), whereas its average is $19.1 million.
  • The largest annual percentage gain for Enanta Pharmaceuticals' Revenue in the last 5 years was 1592.77% (2021), contrasted with its biggest fall of 2710.82% (2021).
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' Revenue stood at $27.6 million in 2021, then fell by 14.7% to $23.6 million in 2022, then dropped by 23.67% to $18.0 million in 2023, then fell by 5.8% to $17.0 million in 2024, then fell by 10.81% to $15.1 million in 2025.
  • Its Revenue stands at $15.1 million for Q3 2025, versus $18.3 million for Q2 2025 and $14.9 million for Q1 2025.